# Enfuvirtide (Fuzeon)

> First-in-class HIV fusion inhibitor peptide.

Source: https://peptides.cafe/peptide/enfuvirtide
Category: Fusion Inhibitor · Antiviral
Tag: FDA-Approved · Antiviral

## Mechanism
36-amino-acid peptide that binds the gp41 subunit of HIV-1 envelope, blocking the conformational change required for viral-host membrane fusion and cell entry.

## Research areas
- Treatment-experienced HIV-1 infection

## Common research protocols
- Twice daily: 90 mg SC twice daily as part of combination ART.

## Study summaries
- "TORO 1 & 2 trials" — NEJM (2003): Added enfuvirtide significantly reduced viral load in treatment-experienced patients.

## Considerations
- FDA-approved.
- Injection-site reactions nearly universal.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.